Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd.

June 07, 2007 08:00 ET

Urodynamix Files Patent Applications

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 7, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) announced that it has filed a series of applications with the United States Patent and Trademark Office for inventions related to medical applications of near-infrared spectroscopy ("NIRS"), the core technology behind the Company's URO-NIRS platform.

Urodynamix has filed patent applications relating to technologies including:

- Methods and systems for detecting Compartment Syndrome

- Methods and systems for diagnosing Erectile Dysfunction

- Assessment of urinary system function by pattern matching

- Methods for monitoring blood flow in the prostate gland

- Digitally-supported physiological sensors

- Light intensity controls for NIRS

- Protection against unintended light exposure

In addition, a patent application relating to the detection of urinary tract syndrome by urination onset delay in animals was submitted to the U.S. Patent and Trademark Office by the University of British Columbia ("UBC") with Urodynamix employees named as co-inventors.

"These patent applications cover commercially significant opportunities for our technology and further strengthen our growing portfolio of intellectual property in medical applications of NIRS," stated Barry Allen, Urodynamix's President & CEO.

Upon the satisfaction of certain conditions, Urodynamix has agreed to issue 150,000 treasury shares to a co-inventor named on one of the patent applications in exchange for full rights to the invention.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urological conditions in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company's disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

In June 2005, Urodynamix acquired exclusive worldwide rights to certain NIRS technology developed at UBC, including technology to aid in the diagnosis of bladder conditions such as urinary incontinence ("UI") and lower urinary tract symptoms ("LUTS") that affect 60 million men and women in North America. Urodynamix is developing a NIRS device for non-invasive urodynamic evaluation, and in May 2007 entered into a worldwide distribution agreement with Laborie Medical Technologies, the world leader in urodynamics equipment.

On behalf of the Board,

Barry Allen, President & CEO

Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information